International Society for Extracellular Vesicles (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 7 (1),
Abstract
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
| Publication DOI: | https://doi.org/10.1080/20013078.2018.1535750 |
|---|---|
| Divisions: | College of Health & Life Sciences > School of Biosciences College of Health & Life Sciences > School of Biosciences > Cell & Tissue Biomedical Research College of Health & Life Sciences College of Health & Life Sciences > Chronic and Communicable Conditions College of Health & Life Sciences > School of Biosciences > Cellular and Molecular Biomedicine College of Engineering & Physical Sciences > School of Infrastructure and Sustainable Engineering > Engineering Systems and Supply Chain Management |
| Funding Information: | Angeles, CA, USA; 26Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA; 27Center for Psychiatry and Neuroscience, INSERM U894, Paris, France; 28Central Research Laboratories, Sysmex Co., Kobe, Japan; 29Centro de Biología Molecular Severo Ochoa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain; 30Children’s Hospital of Los Angeles, Los Angeles, CA, USA; 31Chinese Academy of Sciences, Wenzhou Institute of Biomaterials and Engineering, Wenzhou, China; 32CIC bioGUNE, CIBERehd, Exosomes Laboratory & Metabolomics Platform, Derio, Spain; 33Cincinnati Cancer Center, Cincinnati, OH, USA; 34City of Hope Comprehensive Cancer Center, Beckman Research Institute, Department of Molecular Medicine, Duarte, CA, USA; 35Clínica las Condes, Extracellular Vesicles in Personalized Medicine Group, Santiago, Chile; 36CNC, Coimbra, Portugal; 37CNR Institute of Neuroscience, Milan, Italy; 38Copenhagen Lupus and Vasculitis Clinic, Section 4242 - Rigshospitalet, Copenhagen, Denmark; 39CSGI - Research Center for Colloids and Nanoscience, Florence, Italy; 40Danube University Krems, Department for Biomedical Research and Christian Doppler Laboratory for Innovative Therapy Approaches in Sepsis, Krems an der Donau, Austria; 41Department of Veterans Affairs, San Francisco, CA, USA; 42Duke University Medical Center, Departments of Medicine and Immunology, Durham, NC, USA; 43Duke University, Department of Ophthalmology, Durham, NC, USA; 44Durham VAMC, Medical Research Service, Durham, NC, USA; 45École normale supérieure, Paris, France; 46Department of Pathology, Erasmus MC, Erasmus Optical Imaging Centre, Rotterdam, The Netherlands; 47Department of Urology, Rotterdam, The Netherlands; 48Erasmus MC, Rotterdam, The Netherlands; 49ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland; 50Eulji University, School of Medicine, Daejeon, South Korea; 51Evox Therapeutics Limited, Oxford, UK; 52EVSEARCH.DK, Denmark; 53Exogenus Therapeutics, Cantanhede, Portugal; 54Exosomics Siena SpA, Siena, Italy; 55FAU Erlangen-Nuremberg, Transfusion and Haemostaseology Department, Erlangen, Germany; 56Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia; 57Federal University of Paraná, Department of Genetics, Human Molecular Genetics Laboratory, Curitiba, Brazil; 58FEMTO-ST Institute, UBFC, CNRS, ENSMM, UTBM, Besançon, France; 59Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland; 60Florida State University College of Medicine, Department of Biomedical Sciences, Tallahassee, FL, USA; 61Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Immunotherapy of Human Tumors, Milan, Italy; 62Genome Institute of Singapore, A*STAR, Singapore; 63Georg-Speyer-Haus Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany; 64George Papanicolaou Hospital, Public Cord Blood Bank, Department of Haematology - BMT Unit, Thessaloniki, Greece; 65Georgetown University, Department of Medicine, Washington, DC, USA; 66German Armed Forces Central Hospital, Department of General, Visceral and Thoracic Surgery, Koblenz, Germany; 67German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany; 68German Cancer Research Center (DKFZ), Clinical Cooperation Unit Applied Tumor Biology, Heidelberg, Germany; 69German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, Heidelberg, Germany; 70German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany; 71German Research Center for Environmental Health, Institute for Virology, Munich, Germany; 72Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, REMAR-IVECAT Group, Badalona, Spain; 73Germans Trias i Pujol University Hospital, Nephrology Service, Badalona, Spain; 74Ghent University Hospital, Department of Urology, Ghent, Belgium; 75Ghent University, Department of Radiation Oncology and Experimental Cancer Research, Laboratory of Experimental Cancer Research, Ghent, Belgium; 76Graduate School of Public Health at the University of Pittsburgh, Division of Occupational and Environmental Medicine, Pittsburgh, PA, USA; 77Guangzhou Medical University, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Key Laboratory of Molecular Target & Clinical Pharmacology, Guangzhou, China; 78Haaglanden Medical Center, Department of Neurosurgery, The Hague, The Netherlands; 79Harvard Medical School, Cardiovascular Medicine, Boston, MA, USA; 80Harvard Medical School, Department of Medicine, Boston, MA, USA; 81Harvard University, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 82Harvard University, School of Engineering and Applied Sciences, Cambridge, MA, USA; 83Hasselt University, Biomedical Research Institute (BIOMED), Department of Medicine and Life Sciences, Hasselt, Belgium; 84Hasselt University, Biomedical Research Institute (BIOMED), Hasselt, Belgium; 85Helmholtz Center Munich German Research Center for Environmental Health, Research Unit Gene Vectors, Munich, Germany; 86Helmholtz-Centre for Infection Research, Braunschweig, Germany; 87Helmholtz-Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany; 88Hiroshima University, Institute of Biomedical & Health Sciences, Department of Cellular and Molecular Biology, Hiroshima, Japan; 89Houston Methodist Research Institute, Department of Nanomedicine, Houston, TX, USA; 90Hudson Institute of Medical Research, Melbourne, Australia; 91Icahn School of Medicine at Mount Sinai, Department of Medicine, Cardiology, New York City, NY, USA; 92Icahn School of Medicine at Mount Sinai, New York City, NY, USA; 93IIS-Fundacion Jimenez Diaz-UAM, Department of Nephrology and Hypertension, Madrid, Spain; 94IKERBASQUE Research Science Foundation, Bilbao, Spain; 95Imperial College London, London, UK; 96INEB - Instituto de Engenharia Biomédica, Porto, Portugal; 97INSERM U1063, Université d’Angers, CHU d’Angers, Angers, France; 98INSERM U1068, Aix Marseille University, CNRS UMR7258, Marseille, France; 99INSERM U1110, Strasbourg, France; 100INSERM UMR-S 970, Paris Cardiovascular Research Center, Paris, France; 101Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; 102Institut Curie, CNRS UMR144, PSL Research University, Paris, France; 103Institut Curie, INSERM U932, PSL Research University, Paris, France; 104Institut d’Investigació Germans Trias i Pujol (IGTP), PVREX group, Badalona, Spain; 105Institut Pasteur de Montevideo, Functional Genomics Unit, Montevideo, Uruguay; 106Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR) of Italy, Palermo, Italy; 107Institute of Medical Biology (IMB), Agency for Science and Technology (A*STAR), Singapore; 108Institute of Physiology CAS, Department of Biomaterials and Tissue Engineering, BIOCEV, Vestec, Czech Republic; 109Institute of Physiology CAS, Department of Biomaterials and Tissue Engineering, Prague, Czech Republic; 110Instituto Oswaldo Cruz, Rio de Janeiro, Brazil; 111INSTM - National Interuniversity Consortium of Materials Science and Technology, Florence, Italy; 112Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM), University of Valencia, Polytechnic University of Valencia, Valencia, Spain; 113IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; 114IRCCS - Istituto Ortopedico Rizzoli, Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Bologna, Italy; 115IRCCS Fondazione Don Carlo Gnocchi, Laboratory of Nanomedicine and Clinical Biophotonics (LABION), Milan, Italy; 116IRCCS MultiMedica, Milan, Italy; 117ISGlobal, Hospital Clínic - Universitat de Barcelona, PVREX Group, Barcelona, Spain; 118Istanbul University Oncology Institute, Basic Oncology Department, Istanbul, Turkey; 119Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of Cell Biology, Kraków, Poland; 120James Cook University, Australian Institute of Tropical Health and Medicine, Centre for Biodiscovery and Molecular Development of Therapeutics, Cairns, Australia; 121K.G. Jebsen Brain Tumor Research Centre, Department of Biomedicine, University of Bergen, Bergen, Norway; 122Kansas State University, College of Veterinary Medicine, Manhattan, KS, USA; 123Karolinska Institute, Clinical Research Center, Department of Laboratory Medicine, Stockholm, Sweden; 124Karolinska Institute, Clinical Research Center, Unit for Molecular Cell and Gene Therapy Science, Stockholm, Sweden; 125Karolinska Institute, Department of Medicine and Center for Molecular Medicine, Respiratory Medicine Unit, Stockholm, Sweden; 126Karolinska Institute, Department of Medicine Solna, Division for Immunology and Allergy, Stockholm, Sweden; 127Karolinska Institute, Stockholm, Sweden; 128Kidney Research Centre, Ottawa, Canada; 129KU Leuven (Leuven University), Department of Human Genetics, Leuven, Belgium; 130Kyung Hee University, Department of Applied Chemistry, Yongin, Korea; 131La Trobe University, La Trobe Institute for Molecular Funding is listed only for the corresponding authors. CT’s laboratory is funded by INSERM, Institut Curie, Ministry of Education, and grants from INCa (INCA-11548), French National Research Agency (ANR-10-IDEX-0001-02 PSL* and ANR-11-LABX-0043), SIDACTION (17-1-AAE-1138), Fondation ARC (PGA1 RF20180206962, PJA 20171206453). KWW and CT receive support from NIDA (DA040385). KWW is also supported in part by NIA AG057430, NIDA DA047807 and NIMH MH118164. |
| Additional Information: | © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Uncontrolled Keywords: | ectosomes,exosomes,extracellular vesicles,guidelines,microparticles,microvesicles,minimal information requirements,reproducibility,rigor,standardization,Histology,Cell Biology |
| Publication ISSN: | 2001-3078 |
| Last Modified: | 20 Feb 2026 10:46 |
| Date Deposited: | 19 Aug 2019 09:39 |
| Full Text Link: | |
| Related URLs: |
https://www.sco ... ons/85057143501
(Scopus URL) https://www.tan ... 78.2018.1535750 (Publisher URL) |
PURE Output Type: | Article |
| Published Date: | 2018-12-31 |
| Published Online Date: | 2018-11-23 |
| Accepted Date: | 2018-09-25 |
| Authors: |
, International Society for Extracellular Vesicles
|